Dreyling A. Bendamustine is a hybrid antimetabolite and alkylating agent offering new therapeutic options for the treatment of non-Hodgkin lymphomas. Hematol Meeting Rep [Internet]. 2009 Jun. 23 [cited 2024 Nov. 22];2(5). Available from: https://www.pagepress.org/journals/hmr/article/view/749